Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Preconditioning with Hyperbaric Oxygen in Pancreaticoduodenectomy: a Randomized Double-blind Pilot Study

GERARDO BOSCO, ANDREA CASAROTTO, EMANUELE NASOLE, ENRICO CAMPORESI, ROBERTO SALVIA, FRANCESCO GIOVINAZZO, SARA ZANINI, GIUSEPPE MALLEO, ANDREA DI TANO, ALESSANDRO RUBINI, VINCENZO ZANON, DEVANAND MANGAR and CLAUDIO BASSI
Anticancer Research June 2014, 34 (6) 2899-2906;
GERARDO BOSCO
1Physiology Laboratory, Department of Biomedical Sciences, University of Padova, Padova, Italy
2ATIP Hyperbaric Medical Center, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vincenzo.zanon{at}gmail.com gerardo.bosco{at}unipd.it
ANDREA CASAROTTO
3Laboratory of Translational Surgery, University Laboratory for Medical Research, University of Verona, Verona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EMANUELE NASOLE
4Hyperbaric Medical Center Villafranca, Verona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ENRICO CAMPORESI
5Anesthesiology FGTBA, Tampa General Hospital, Tampa, FL, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ROBERTO SALVIA
3Laboratory of Translational Surgery, University Laboratory for Medical Research, University of Verona, Verona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FRANCESCO GIOVINAZZO
3Laboratory of Translational Surgery, University Laboratory for Medical Research, University of Verona, Verona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SARA ZANINI
3Laboratory of Translational Surgery, University Laboratory for Medical Research, University of Verona, Verona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIUSEPPE MALLEO
3Laboratory of Translational Surgery, University Laboratory for Medical Research, University of Verona, Verona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ANDREA DI TANO
1Physiology Laboratory, Department of Biomedical Sciences, University of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALESSANDRO RUBINI
1Physiology Laboratory, Department of Biomedical Sciences, University of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
VINCENZO ZANON
1Physiology Laboratory, Department of Biomedical Sciences, University of Padova, Padova, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: vincenzo.zanon{at}gmail.com gerardo.bosco{at}unipd.it
DEVANAND MANGAR
5Anesthesiology FGTBA, Tampa General Hospital, Tampa, FL, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CLAUDIO BASSI
3Laboratory of Translational Surgery, University Laboratory for Medical Research, University of Verona, Verona, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

In a prospective randomized double-blind study, we evaluated the post-operative biological and clinical effects of a single preoperative hyperbaric-treatment the day before surgery for pancreatic ductal adenocarcinoma. Patients and Methods: Twenty one patients were randomized and divided into two groups: group-A (10 patients, 48%) were exposed to a HyperBaric Oxygen (HBO) session the day before intervention [Pre-Intervention Day (PID)], group-B (11 patients, 52%) breathed air for 40 min in a hyperbaric chamber pressurized to 1.15 ATA (placebo group). For all patients blood samples were obtained before HBO treatment or the placebo procedure (T0); at the end of HBO session or placebo procedure (T1); on the first post-operative day (POD)(T2) and on seventh POD(T3) day, measuring interleukin (IL)-1, IL-6, IL-8, IL-10, IL-12 and TNF-α, recording postoperative pancreatic fistula (POPF), biliary-fistula, fever, intra-abdominal abscess, bleeding, pulmonary complications, delayed gastric emptying and requirement for post-operative antibiotics. The results of the present pilot study suggest that a single preoperative hyperbaric oxygen treatment on the day before surgery may reduce the complication rate in pancreatic resection.

  • Pancreaticoduodenectomy
  • HBO
  • hyperbaric
  • pre-conditioning
  • surgery

Hyperbaric oxygen (HBO) therapy involves the intermittent inhalation of 100% oxygen in chambers pressurized between 1.5 and 3.0 atmosphere absolute (ATA) (3). HBO increases both dissolved oxygen and the partial pressure of oxygen in plasma (4, 22). HBO is commonly used in the treatment of decompression sickness, carbon monoxide intoxication, arterial gas embolism, necrotizing soft tissue infections, chronic skin ulcers, severe multiple trauma with ischemia and ischemic diabetic foot ulcers (3-14). A possible mechanism of HBO mediating beneficial effects has been described as attenuation of the production of pro-inflammatory cytokines in response to an inflammatory stimulus such as surgery (15, 38) and modulation of the immune response (3, 5). Previous data by Yang and colleagues on animals demonstrated that HBO inhibits TNF-α production during intestinal ischemia-reperfusion (30) and it has a beneficial effect, mediated by decreased production of both TNF-α and IL-1β, on indomethacin-induced enteropathy (31). The positive role of HBO in human surgery has been demonstrated in cardiovascular (16, 17), orthopedic surgery (18), and after liver transplantation, as reported by Franchello et al. which documented a reduction of ischemic areas and an increase of intrahepatic arterial vascularisation by collateral vessels after 20 HBO sessions in a patient affected by Hepatic Artery Thrombosis (HAT) after liver transplantation (19). Pancreatico-duodenectomy (PD) is associated with a significant complication rate ranging between 30%-60% (20), often with prolonged hospital stay and economic resource utilization (21).

The main objective of the present pilot study on patients receiving PD was to identify differences between the concentration of inflammatory cytokines in two groups of patients exposed to HBO or sham prior to PD procedure. A secondary objective was assessment and comparison of the complication rate and duration of hospital stay between the two groups.

Patients and Methods

Ethics approval was obtained from local regional ethics committee of the University of Verona, Italy (n. 2176/2012). The study was a prospective, randomized double-blind study lasting 6 months. Patients were randomized at the Hyperbaric Institute SpA of Villafranca (Verona, Italy) by gaining exposure to HBO treatment, using a computer-generated allocation schedule and were divided into two groups. Twenty-four hours before the planned PD, patients of group “A” were submitted to a HBO session, while Patients of group “B” breathed air in a multiplace hyperbaric chamber pressurized to 1.15 ATA (sham).

All patients received medical evaluation to exclude absolute contraindications to hyperbaric therapy, including electrocardiography, thoracic X-Ray and the count of white cells, red cells, haemoglobin and hematocrit. Patients aged >80 years or <18 years, or affected by cavitary or current tuberculosis, bronchiectasis, lung abscess, previous spontaneous pneumothorax or traumatic current not already drained, heart failure, pulmonary edema, acute purulent sinusitis, severe glaucoma, hypercapnic respiratory insufficiency with pCO2 >60 mmHg, previous rupture of inner ear's round or oval membrane, sinus bradycardia, inflammation of the upper respiratory tract, parenchymal or mechanical bronchoconstrictions or epilepsy, were excluded from the study.

The HBO session was a single hyperbaric exposure at 2.5 ATA for a duration of 116 min: 12-15 min of compression time, 3 periods of 24 min each on 100% O2 at maximum pressure, interrupted by two air breathing periods of 5 min each. Oxygen was delivered to patients via a tight-fitting mask. Decompression to 1 ATA occurred over 18 min, with 3 min at 1.3 ATA. Oxygen was administered starting at 1.6 ATA and during decompression from 2.5 to 1.3 ATA. During the entire exposure time an experienced hyperbaric-trained physician was inside the hyperbaric chamber as required by the practice quality provisions of the Hyperbaric Institute.

In all patients, small venous blood samples were obtained before (T0) and at the end (T1) of HBO session or placebo procedure; at the first post-operative day (POD) (T2) and in the seventh POD (T3). Venous blood samples were collected in heparinized tubes and the plasma obtained stored at −80°C. The BDTM CBA Human Inflammatory Cytokines kit number 551811 (Becton, Dickinson and Company BD Biosciences San Jose, CA, USA) was used to measure interleukin (IL)-1, IL-6, IL-8, IL-10, IL-12p70 and TNF-α. The FCAP ArrayTM software (Becton, Dickinson and Company BD Biosciences San Jose, CA 95131) was used to generate results in graphical and tabular format.

The following postoperative complications were recorded: post-operative pancreatic fistula (POPF), biliary fistula, fever, intra-abdominal fluid collections, defined as the presence of fluid collection of 5 cm in diameter with or without clinical significance at CT scan or ultrasound presence, bleeding, pulmonary complications, including pneumonia, bronchospasm, respiratory failure and prolonged mechanical ventilation delayed gastric emptying, defined as the need of nasogastric tube decompression for 10 days and the use of postoperative antibiotics. For the evaluation of the complications we followed carefully the definition proposed by Bassi et al. (23) and we classified the POPF using the definition proposed by ISGPF (24). Pulmonary complications were diagnosed from presence of three of the following: fever, purulent sputum, tachycardia, tachypnea, inspiratory crackles, bronchial breathing, abnormal chest x-ray, arterial hypoxemia, positive stain and culture, as described by Bassi et al. (62).

For statistical analysis, the Chi-squared test after Yates and Fisher tests, when necessary, were used. All statistical tests were two-sided. A p-value less than 0.05 indicated statistical significance. All statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) software version 19.0 (SPSS, Chicago, IL).

Results

From 01-02-2012 to 31-07-2012 in our Department 127 patients underwent pancreatic resection (81 [63.8%] pylorus preserving pancreatico-duodenectomy [PPPD], 9 [7.1%] Whipple procedures, 28 [22%] distal pancreatic resections, 7 [5.5%] intermedial pancreatic resections and 2 [1.6%] total pancreatic resections). Out of these patients, 32 were recruited to the present study (25.2%) using “geographic criteria”. In fact, all patients recruited in the study lived near the Hyperbaric Institute (maximum 150 km) in order to carry-out the tests and the bureaucracy needed for the HBO therapy and preconditioning. Out of these patients, 5 (15.6%) presented a “borderline” neoplasia when the tumor involved the celiac axis or the superior mesenteric artery (unresectable primary tumor) at CT scan (Stage III sec. AJCC) and they were treated with thermoablation, while other 6 (18.8%) presented liver metastasis (Stage IV sec. AJCC). The remaining 21 (65.6%) patients presented with resectable pancreatic cancer. From these last patients, 11 were randomized to the placebo group (52.4%) and the other 10 (47.6%) to the HBO group. All patients recruited in this study had a resectable lesion and underwent PPPD. The flow chart of the randomization is described in Figure 1.

The results of serum concentrations of IL-1, IL-6, IL-8, IL-10, TNF-α, IL-12p70 at T0, T1, T2 and T3 are listed below (Table I). The maximum concentration of cytokines was at T2. Level of IL-6 was significantly lower in “A” group, while IL-10 level was significantly higher after HBO exposure.

Table I shows the correlation between the age distribution in placebo group and HBO group, the tumor histology, the incidence of POPF and biliary fistula, the incidence of fever, postoperative use of antiobiotics, pulmonary complications, delayed gastric empty (DGE) and bleeding by group. In the group of 21 patients that underwent surgical procedure, 14 (66.7%) underwent PPPD for pancreatic ductal adenocarcinoma and 7 (33.3%) for benign neoplasms (3 main-duct intraductal papillary mucinous neoplasms [IPMNs], 2 mucinous cystic neoplasms [MCNs], 1 symptomatic serous cystadenoma [SCA] and 1 chronic pancreatitis).

The incidence of DGE (19%) was not statistically different between the 2 groups: 3 in HBO group and 1 in placebo group. There were 5 instances (23.8%) of postoperative bleeding (3 in HBO group and 2 in placebo group, PNS). One patient (placebo group) required laparotomy 2 h after the initial surgery for common hepatic artery repair. In the randomized patients, there were 6 POPF (28.6%) (2 type A, 2 type B and 2 type C sec. ISGPF), 3 in the HBO group, 3 in the placebo group. There was one biliary fistula (4.8%) in a patient of the placebo group. Significant differences in favor of HBO were found in pulmonary complications (none in HBO group versus 6 in placebo group; p=0.023).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Flow-chart for randomization.

In the patients that underwent PPPD, 6 pulmonary infections were present, significantly less frequent in the HBO group vs. placebo group (p=0.023), but were not correlated with gender, histology, POPF, biliary fistula, fever, use of antibiotics or age (Table II). There were 3 pulmonary infections in males (50%) and 3 in females (50%). In 2 cases (33.3%) pulmonary infections occurred in patients >65 years. In 2 cases (33.3%), POPF and pulmonary infection were present in the same patient and in 1 case (16.7%) the pulmonary infection was present with biliary fistula. Use of antibiotics was not significantly different between groups (4 in HBO group and 6 in placebo group, p=0.67) and the incidence of fever was the same in the two groups (4 in HBO group and 4 in sham group, p=1).

Table III shows the correlation between gender, POPF, biliary fistula, HBO, fever, DGE and the concentrations of cytokines. IL-1 and TNF-α were correlated with fever (p=0.006 and p=0.04 respectively). IL-6 was correlated with biliary fistula and its concentration was affected by HBO exposure, as was IL-10 (p=0.035). TNF-α was also correlated with POPF (p=0.026). On the other hand, IL-8 and IL-12 were not influenced by HBO exposure (p=0.065 and p=0.69 respectively).

The basal mean level of cytokines in patients with unresectable pancreatic cancer was statistically different from patients with resectable pancreatic cancer, especially for IL-6 and IL-8 (p=0.0001 and p=0.046 respectively).

Discussion

In the present study, we evaluated post-operative biological and clinical effects of preoperative HBO in patients undergoing pancreaticoduodenectomy. There were no complications from the hyperbaric exposure in all patients.

Pre-oxygenation studies. As already known, modulation of the inflammatory response resulting from exposure to oxygen in a hyperbaric chamber modifies the synthesis of growth factors (VEGF) (1), reduces the concentration of pro-inflammatory cytokines, and modulates tissue myeloperoxidase and lipoperoxides (2).

During the reperfusion of ischemic tissue, oxygenated blood increases number and activities of oxidants generated in tissues. Reperfusion increases the hazardous effects of early ischemic injury by release of cytokines and reactive oxygen species (ROS) such as hydroxyl radical (OH−), superoxide radical (O2−), and hydrogen peroxide (H2O2) and by the activation of complement system. This phenomenon has been broadly named “ischemia-reperfusion (I/R) injury”. Neural tissues as well as most visceral tissues can be all involved in I/R, and animal models of different organs' tolerance and vulnerability have been widely studied (39).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Wilcoxon matched pairs test between HBO and placebo conditions for IL-1, IL-6, IL-8, IL-10, IL-12, TNF measure at T0, T1, T2, T3.

A critical role in ischemia-reperfusion injury is played by TNF-α and IL-1β, as shown by Yang and Bosco (30-31) the increased of TNF-α serum levels, occur in the early phase of inflammation, whereas elevation of IL-1β levels occur in the later phase, suggesting that this cytokine could sustain the inflammation process. The same authors showed how an ischemia-reperfusion injury could strike multiple organs: increased TNF-α serum levels, sequel intestinal ischemia-reperfusion injury, is responsible of acute lung injury (31). In fact, TNF-α goes into the systemic circulation and is received by resident population of macrophages in liver and lungs, promoting the inflammation process also in other organs (33).

There exist many studies investigating I/R injury in different tissues, such as kidney, liver, lung, testis, brain, heart muscle, and skeletal muscle in the literature (34). I/R injury in skeletal muscles (32) and also in bone may also occur with vascular problems, including atherosclerotic occlusive disease, arterial thrombosis, or arterial embolism, after organ transplantation, cardiovascular surgery, and vascular trauma (35). In addition, limb ischemia-reperfusion occurs often in surgical procedures, when using a tourniquet to provide a bloodless surgical field (32, 35). Although hyperbaric oxygen (HBO) causes oxidative stress (36, 37) similar to ischemic-preconditioning (PC), HBO-PC generates a non-lethal level of ROS, which induces ischemic tolerance and has protective effect after severe ischemic attacks (37, 38). Certain studies have shown that HBO-PC reduces I/R damage by its antioxidant effect, hyperoxygenation, and vasoconstriction. Furthermore, HBO is believed to exert its antioxidant effect by reducing leucocyte recruitment and activation, edema, cellular necrosis, and increasing the efficacy of antioxidant enzymes (32, 36, 37).

Despite improvements in surgical techniques and in anesthetic management, ischemia-reperfusion injury remains an inevitable event of cardiac surgery, resulting in significant postoperative complications and multiple-organ dysfunction. To date, brain injury after cardio-pulmonary bypass (CPB) for cardiac surgery has been well-documented. Sequelae can be as mild as postoperative cognitive dysfunction and postoperative delirium and as severe as stroke (40). The etiology of cerebral injuries is probably multi-factorial, from an interaction among cerebral microemboli, global cerebral hypoperfusion, inflammation, cerebral temperature modulation and genetic susceptibility (41). Ischemia-reperfusion injury during CPB also leads to myocardial stunning, necrosis, or apoptosis that manifest clinically either acutely as low cardiac output or chronically as heart failure (42).

Preconditioning is the application of an intervention to activate endogenous protective mechanisms to reduce the morphological and functional sequelae of a subsequent ischemia insult. The phenomenon of ischemic preconditioning was first described in a canine myocardium ischemia-reperfusion injury model (43) and subsequently was shown in the brain (44). Since then, intense research in the field of pharmacology ensued to identify agents such as volatile anesthetic agents and ischemic preconditioning (45-47) that could duplicate the protective effects of preconditioning for cardiac surgery.

Despite the increasing number of basic science publications on this issue, studies describing HBO preconditioning in the clinical practice of general surgery remain scarce. To date, only a few studies have investigated the preconditioning effects of HBO in the human brain and myocardium (48). In 2004 Sharifi et al. described the use of HBO to inhibit restenosis after PTCI in acute myocardial infarction (49). In 2005, Alex et al. observed that repetitive pre-treatment with three sessions of HBO at 2.4 ATA before on-pump coronary artery bypass graft (CABG) surgery reduced neuropsychometric dysfunction and modulated favorably the inflammatory response after CPB (16). Yogaratnam et al. reported that preconditioning with a single session of HBO at 2.5 ATA before on-pump CABG surgery improved left ventricular stroke work post-CABG surgery while reducing intraoperative blood loss, intensive care unit (ICU) length of stay, and postoperative complications (17).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Correlation between age, histology, POPF, biliary fistula, fever, postoperative antibiotics use, pulmonary complications, DGE, bleeding and HBO exposition.

Recently, Li et al. aimed to determine whether HBO preconditioning could decrease the release of cerebral and myocardial biochemical markers. Endpoints of this study included serum troponin I, inotrope usage, ventilator hours, length of ICU stay, postoperative length of hospital stay, hemodynamic parameters, and serum CAT activity (37).

In conclusion, in this randomized pilot study for 32 patients selected using geographical criteria affected by pancreatic cancer, several novel findings came to light, as for the first time we evaluated the biological and clinical effects of HBO in patients undergoing pancreatic surgery.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Correlation between gender, POPF, biliary fistula, HBO, fever, DGE and the concentrations of cytokines.

Biological effects in our patients. The preoperative hyperbaric therapy modulates the levels of IL-6 (p=0.009) and IL-10 (p=0.03). It also seems that there is a statistically significant relationship between IL-6 and biliary fistula (p=0.009). IL-1 (p=0.006) and TNF-α (p=0.04) are correlated with the hyperpyrexia and, in addition, TNF-α should be in relation with the POPF (p=0.019). The relationship of IL-1 with hyperbaric therapy has been demonstrated only in orthopedic surgery (18) and in perianal Crohn's disease treatment by Weisz et al. (26).

In the present study we found a relationship between HBO exposure and the modulation of the level of IL-6 and IL-10 with a relationship between IL-6 and biliary fistula, IL-1 and fever and a doubtful correlation between TNF-α and POPF. Preoperative HBO action significantly decreased serum concentration of IL-6 (p=0.009). In addition, we observed a correlation between the occurrence of biliary fistula and serum level of IL-6 (p=0.04).

Patients with unresectable tumors with metastasis (Stage IV sec. AJCC) or with infiltration of adjacent structures (stage III sec. AJCC) had a higher level of interleukins than resectable patients. This difference is very marked as regards the IL-6 (p=0.0001, resectable vs. unresectable) and conceivably could play a role in determining tumor staging. This relationship was already suggested by Okisu et al. (27) that also observed that the interaction with androgens receptors' and the cytokine concentration were in relation with mortality. Talar-Wojnarowska et al. demonstrated that elevated levels of IL-6 could be related to a high metastatic potential through the stimulation of growth factors, including VEGF (28). Pini et al. confirmed it in mice pretreated with anti-IL-6 antibodies that it participates in delayed recovery from acute inflammation and may favor development of a pro-tumorigenic environment through prolonged activation of STAT-3, induction of MMP-7 and sustained production of chemokines (50). Boreddy et al. demonstrated that IL-6 drastically increased the expression of HIF-1α (hypoxia inducible factor) and VEGF expression that play a crucial role in pancreatic cancer progression (51).

On the other hand, in a recent article, Grote et al. demonstrated that IL-6 does not seem to have a role with respect to risk of pancreatic cancer (52).

IL-10 is an anti-inflammatory cytokine with protective activity, its post-operative serum concentration results are higher in patients who underwent HBO (p=0.03), such as literature showed (29). In 2011, Ribatti et al. (53) demonstrated that through the secretion of immunosuppressive cytokines such as IL-10, mast cells down-regulate the immune response to tumors. Mast cells, in fact, produce and secrete potent angiogenic molecules, and have been implicated in angiogenesis in various malignancies, including laryngeal squamous cell carcinomas, lung cancers and malignant melanomas (54).

The levels of IL-8, IL-10 and TNF-α were not modulated by HBO.

Clinical effects in our patients. We found a relationship between the different clinical variables and cytokines such as the correlation between fever and IL-1 and TNF-α and the pancreatic fistula with only TNF-α. Patients who underwent a hyperbaric therapy session expressed a reduction in postoperative pulmonary infections (p=0.023 vs. placebo) but this effect was not associated with a statistically significant decrease in the length of hospital stay (p=0.063), fever (p=0.146) or use of antibiotics (p=0.063). The occurrence of POPF can't be explained only by an altered inflammatory state (23-25) so the modulation of the inflammatory response has only a marginal role (p=1). In fact, the risk of POPF formation has been shown to be directly proportional to the consistency of the residual organ by virtually all authors (55-63) and is further supported by the fact that anastomosis performed on chronic pancreatitis patients with fibrotic glands has a significantly reduced clinical incidence of complications related to anastomosis (64). In conclusion, the preoperative exposure to hyperbaric environment is safe and can be applied to all patients after careful clinical evaluation and identification of absolute contraindications as per chemotherapic protocol (65).

IL-6 expression in these cases is usually increased and particularly related with the biliary fistula, but shows itself to be sharply influenced under hyperbaric oxygen exposure conditions. This may suggest a potential HBO in decreasing the incidence of postoperative biliary fistulas and pneumonia. Moreover this cytokine may be useful as a prognostic marker or indicator of disease progression. Maybe it is possible that high basal levels of IL-6 may be related to the presence of a tumor in advanced stage and therefore the patient is candidabile to neoadjuvant treatment.

In conclusion, in this pilot randomized study we found that a single preoperative HBO session the day before pancreatic surgery should modulate the inflammatory response, especially for IL-6 and IL-10 with a decrease in postoperative pneumonia. Further studies are required to evaluate the response to HBO in a larger number of patients and in other surgical procedures, especially major surgeries leading to postoperative ICU admission.

Acknowledgements

The Authors are grateful to Professor Richard Moon for his generous input during the preparation of the manuscript.

  • Received February 17, 2014.
  • Revision received April 28, 2014.
  • Accepted April 30, 2014.
  • Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Jung S,
    2. Wermker K,
    3. Poetschik H,
    4. Ziebura T,
    5. Kleinheinz J
    : The impact of hyperbaric oxygen therapy on serological values of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF). Head Face Med 6: 29-34, 2010.
    OpenUrlPubMed
  2. ↵
    1. Godman CA,
    2. Chheda KP,
    3. Hightower LE,
    4. Perdrizet G,
    5. Shin DG,
    6. Giardina C
    : Hyperbaric oxygen induces a cytoprotective and angiogenic response in human microvascular endothelial cells. Cell Stress Chaperones 15(4): 431-442, 2010.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Tibbles PM,
    2. Edelsberg JS
    : Hyperbaric oxygen therapy. N Engl J Med 334: 1642-1648, 1996.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Leach RM,
    2. Rees PJ,
    3. Wilmhurst P
    : Hyperbaric oxygen therapy. Br Med J 317: 1140-1143, 1998.
    OpenUrlFREE Full Text
  5. ↵
    1. Katz M,
    2. Alvarez A,
    3. Kirsner R,
    4. Eaglstein W
    : Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. J Am Acad Dermatol 25: 1054-1058, 1991.
    OpenUrlPubMed
    1. La Van FB,
    2. Hunt TK
    : Oxygen and wound healing. Clin Plast Surg 17: 463-472, 1990.
    OpenUrlPubMed
    1. Wada J,
    2. Iwa T
    1. Winter GD,
    2. Perrins DJD
    : Effects of hyperbaric oxygen treatment on epidermal regeneration, in: Wada J, Iwa T (eds.). Proceeding of the Fourth International Congress on Hyperbaric Medicine, Igaku Shoin, Tokyo, p. 363, 1970.
    1. Kinighton DR,
    2. Halliday B,
    3. Hunt TK
    : Oxygen as an antibiotic: a comparison of the effects of inspired oxygen concentration and antibiotic administration on in vivo bacterial clearance. Arch Surg 121: 191-195, 1986.
    OpenUrlCrossRefPubMed
    1. Verklin RN,
    2. Mandell GL
    : Alteration of effectiveness of antibiotics by anaerobiosis. J Lab Clin Med 89: 65-71, 1977.
    OpenUrlPubMed
    1. Ciaravino ME,
    2. Friedell ML,
    3. Kommerlocher TC
    : Is hyperbaric oxygen a useful adjuvant in the management of problem lower extremity wounds? Ann Vasc Surg 10: 558-562, 1996.
    OpenUrlCrossRefPubMed
    1. Abidia A,
    2. Laden G,
    3. Kuhan G,
    4. Johnson BF,
    5. Wilkinson AR,
    6. Renwick PM,
    7. Masson EA,
    8. McCollum PT
    : Role of hyperbaric oxygen therapy in ischemic, diabetic, lower-extremity ulcers: double-blind randomized controlled trial (surgical research society abstracts). Br J Surg 88: 744, 2001.
    OpenUrl
    1. Zamboni WA,
    2. Wong HP,
    3. Stephenson LL,
    4. Pfeifer MA
    : Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study. Undersea Hyperb Med 24: 175-179, 1997.
    OpenUrlPubMed
    1. Faglia E,
    2. Favales F,
    3. Aldeghi A,
    4. et al
    : Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. Diabetes Care 19(12): 1338-1343, 1996.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Doctor N,
    2. Pandya S,
    3. Supe A
    : Hyperbaric oxygen therapy in diabetic foot. J Postgrad Med 38: 112-114, 1992.
    OpenUrlPubMed
  7. ↵
    1. Kudchodkar B,
    2. Jones H,
    3. Simecka J,
    4. Dory L
    : Hyperbaric oxygen treatment attenuates the pro-inlammatory and immune response in apolipoprotein E knockout mice. Clin Immunol 128(3): 435-441, 2008.
    OpenUrlPubMed
  8. ↵
    1. Alex J,
    2. Laden G,
    3. Cale AR,
    4. Bennett S,
    5. Flowers K,
    6. Madden L,
    7. Gardiner E,
    8. McCollum PT,
    9. Griffin SC
    : Pretreatment with hyperbaric oxygen and its effect on neuropsychometric dysfunction and systemic inflammatory response after cardiopulmonary bypass: a prospective randomized double-blind trial. J Thorac Cardiovasc Surg 130(6): 1623-1630, 2005.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Yogaratnam JZ,
    2. Laden G,
    3. Guvendik L,
    4. Cowen M,
    5. Cale A,
    6. Griffin S
    : Hyperbaric oxygen preconditioning improve myocardial function, reduces lenght of intensive care stay, and limits complications post coronary artery bypass graft surgery. Cardiovasc Revasc Med 11: 8-19, 2010.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Niu CC,
    2. Yuan LJ,
    3. Chen LH,
    4. Lin SS,
    5. Tsai TT,
    6. Liao JC,
    7. Lai PL,
    8. Chen WJ
    : Beneficial effects of hyperbaric oxygen on human degenerated intervertebral disk cells via suppression of IL-1β and p38 MAPK signal. J Orthop Res 29(1): 14-19, 2011.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Franchello A,
    2. Ricchiuti A,
    3. Maffi L,
    4. Romagnoli R,
    5. Salizzoni M
    : Hyperbaric oxygen therapy in liver transplantation; is its use limited to the management of hepatic artery thrombosis? Transpl Int 23(9): e49-50, 2010.
    OpenUrlPubMed
  12. ↵
    1. Vin Y,
    2. Sima CS,
    3. Getrajdman GI,
    4. Brown KT,
    5. Covey A,
    6. Brennan MF,
    7. Allen PJ
    : Management and outcomes of postpancreatectomy fistula, leak, and abscess: results of 908 patients resected at a single institution between 2000 and 2005. J Am Coll Surg 207: 490-498, 2008.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Pratt WB,
    2. Maithel SK,
    3. Vanounou T,
    4. Huang ZS,
    5. Callery MP,
    6. Vollmer CM Jr..
    : Clinical and economic validation of the International Study Group of Pancreatic Fistula (ISGPF) classification scheme. Ann Surg 245: 443-451, 2007.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Kindwall E,
    2. Whelan H
    : Hyperbaric Medicine Practice. 2nd ed. Flsgstaff, AZ: Best Publishing Company Chap 1: 18-20, 25, 29, 30, 2004.
  15. ↵
    1. Bassi C,
    2. Falconi M,
    3. Molinari E,
    4. Salvia R,
    5. Butturini G,
    6. Sartori N,
    7. Mantovani W,
    8. Pederzoli P
    : Reconstruction by pancreaticojejunostomy versus pancreaticogastrostomy following pancreatectomy: results of a comparative study. Ann Surg 242(6): 767-71, discussion 771-773, 2005.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Bassi C,
    2. Dervenis C,
    3. Butturini G,
    4. Fingerhut A,
    5. Yeo C,
    6. Izbicki J,
    7. Neoptolemos J,
    8. Sarr M,
    9. Traverso W,
    10. Buchler M
    : Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery 138(1): 8-13, 2005.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Hackert T,
    2. Werner J,
    3. Büchler MW
    : Postoperative pancreatic fistula. Surgeon 9(4): 211-217, 2011.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Weisz G,
    2. Lavy A,
    3. Adir Y,
    4. Melamed Y,
    5. Rubin D,
    6. Eidelman S,
    7. Pollack S
    : Modification of in vivo and in vitro TNF-alpha, IL-1, and IL-6 secretion by circulating monocytes during hyperbaric oxygen treatment in patients with perianal Crohn's disease. J Clin Immunol 17(2): 154-159, 1997.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Okitsu K,
    2. Kanda T,
    3. Imazeki F,
    4. Yonemitsu Y,
    5. Ray RB,
    6. Chang C,
    7. Yokosuka O
    : Involvement of Interleukin-6 and Androgen Receptor Signaling in Pancreatic Cancer. Genes Cancer 1(8): 859-867, 2010.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Talar-Wojnarowska R,
    2. Gasiorowska A,
    3. Smolarz B,
    4. Romanowicz-Makowska H,
    5. Kulig A,
    6. Malecka-Panas E
    : Clinical significance of interleukin-6 (Il-6) gene polymorphism and Il-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci 54: 683-689, 2009.
    OpenUrlCrossRefPubMed
  21. ↵
    1. Buras JA,
    2. Holt D,
    3. Orlow D,
    4. Belikoff B,
    5. Pavlides S,
    6. Reenstra WR
    : Hyperbaric oxygen protects from sepsis mortality via an interleukin-10-dependent mechanism. Crit Care Med 34(10): 2624-2629, 2006.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Yang ZJ,
    2. Bosco G,
    3. Montante A,
    4. Ou XI,
    5. Camporesi EM
    : Hyperbaric O2 reduces intestinal ischemia-reperfusion-induced TNF-α production and lung neutrophil sequestration. Eur J Appl Physiol 85(1-2): 96-103, 2001.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Yang Z,
    2. Nandi J,
    3. Wang J,
    4. Bosco G,
    5. Gregory M,
    6. Chung C,
    7. Xie Y,
    8. Yang X,
    9. Camporesi EM
    : Hyperbaric oxygenation ameliorates indomethacin-induced enteropathy in rats by modulating TNF-α and IL-1β production. Dig Dis Sci 51(8): 1426-1433, 2006.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Bosco G,
    2. Yang ZJ,
    3. Nandi J,
    4. Wang J,
    5. Chen C,
    6. Camporesi EM
    : Effects of hyperbaric oxygen on glucose, lactate, glycerol and anti-oxidant enzymes in the skeletal muscle of rats during ischaemia and reperfusion. Clin Exp Pharmacol Physiol 34(1-2): 70-76, 2007.
    OpenUrlCrossRefPubMed
  25. ↵
    1. Yu SY,
    2. Chiu JH,
    3. Yang SD,
    4. Yu HY,
    5. Hsieh CC,
    6. Chen PJ,
    7. Lui WY,
    8. Wu CW
    : Preconditioned hyperbaric oxygenation protects the liver against ischemia-reperfusion injury in rats. J Surg Res 128(1): 28-36, 2005.
    OpenUrlPubMed
  26. ↵
    1. Grisotto PC,
    2. dos Santos AC,
    3. Coutinho-Netto J,
    4. Cherri J,
    5. Piccinato CE
    : Indicators of oxidative injury and alterations of the cell membrane in the skeletal muscle of rats submitted to ischemia and reperfusion. J Surg Res 92(1): 1-6, 2000.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Ozyurt H,
    2. Ozyurt B,
    3. Koca K,
    4. Ozgocmen S
    : Caffeic acid phenethyl ester (CAPE) protects ratskeletal muscle against ischemia-reperfusion-induced oxidative stress. Vascul Pharmacol 47(2-3): 108-112, 2007.
    OpenUrlPubMed
  28. ↵
    1. Ay H,
    2. Topal T,
    3. Uysal B,
    4. Ozler M,
    5. Oter S,
    6. Korkmaz A,
    7. Dündar K
    : Time dependent course of hyperbaric oxygen-induced oxidative effects in rat lung and erythrocytes. Clin Exp Pharmacol Physiol 34(8): 787-791, 2007.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Li J,
    2. Liu W,
    3. Ding S,
    4. Xu W,
    5. Guan Y,
    6. Zhang JH,
    7. Sun X
    : Hyperbaric oxygen preconditioning induces tolerance against brain ischemia-reperfusion injury by upregulation of antioxidant enzymes in rats. Brain Res 1210: 223-229, 2008.
    OpenUrlCrossRefPubMed
  30. ↵
    1. MacFarlane C,
    2. Cronjé FJ
    : Hyperbaric oxygen and surgery. S Afr J Surg 39(4): 117-121, 2001.
    OpenUrlPubMed
  31. ↵
    1. Gao L,
    2. Taha R,
    3. Gauvin D,
    4. Othmen LB,
    5. Wang Y,
    6. Blaise G
    : Postoperative cognitive dysfunction after cardiac surgery. Chest 128(5): 3664-70, 2005.
    OpenUrlCrossRefPubMed
  32. ↵
    1. Sato Y,
    2. Laskowitz DT,
    3. Bennett ER,
    4. Newman MF,
    5. Warner DS,
    6. Grocott HP
    : Differential cerebral gene expression during cardiopulmonary bypass in the rat: Evidence for apoptosis? Anesth Analg 94(6): 1389-1394, 2002.
    OpenUrlPubMed
  33. ↵
    1. Bolli R,
    2. Becker L,
    3. Gross G,
    4. Mentzer R Jr..,
    5. Balshaw D,
    6. Lathrop DA
    : Myocardial protection at a crossroads: The need for translation into clinical therapy. Circ Res 95(2): 125-134, 2004.
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Murry CE,
    2. Jennings RB,
    3. Reimer KA
    : Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74(5): 1124-1136, 1986.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Kitagawa K,
    2. Matsumoto M,
    3. Tagaya M,
    4. Hata R,
    5. Ueda H,
    6. Niinobe M,
    7. Handa N,
    8. Fukunaga R,
    9. Kimura K,
    10. Mikoshiba K,
    11. et al
    : ‘Ischemic tolerance’ phenomenon found in the brain. Brain Res 528(1): 21-24, 1990.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Haroun-Bizri S,
    2. Khoury SS,
    3. Chehab IR,
    4. Kassas CM,
    5. Baraka A
    : Does isoflurane optimize myocardial protection during cardiopulmonary bypass? J Cardiothorac Vasc Anesth 15(4): 418-421, 2001.
    OpenUrlCrossRefPubMed
  37. ↵
    1. Guarracino F,
    2. Landoni G,
    3. Tritapepe L,
    4. Pompei F,
    5. Leoni A,
    6. Aletti G,
    7. Scandroglio AM,
    8. Maselli D,
    9. De Luca M,
    10. Marchetti C,
    11. Crescenzi G,
    12. Zangrillo A
    : Myocardial damage prevented by volatile anesthetics: a multicenter randomizedcontrolled study. J Cardiothorac Vasc Anesth 20(4): 477-483, 2006.
    OpenUrlCrossRefPubMed
    1. Yellon DM,
    2. Alkhulaifi AM,
    3. Pugsley WB
    : Preconditioning the human myocardium. Lancet 342(8866): 276-277, 1993.
    OpenUrlCrossRefPubMed
  38. ↵
    1. Hausenloy DJ,
    2. Mwamure PK,
    3. Venugopal V,
    4. Harris J,
    5. Barnard M,
    6. Grundy E,
    7. Ashley E,
    8. Vichare S,
    9. Di Salvo C,
    10. Kolvekar S,
    11. Hayward M,
    12. Keogh B,
    13. MacAllister RJ,
    14. Yellon DM
    : Effect of remote ischemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: A randomized controlled trial. Lancet 370(9587): 575-579, 2007.
    OpenUrlCrossRefPubMed
  39. ↵
    1. Li Y,
    2. Dong H,
    3. Chen M,
    4. Liu J,
    5. Yang L,
    6. Chen S,
    7. Xiong L
    : Preconditioning with repeated Hyperbaric Oxygen induces myocardial and cerebralprotection in patients undergoing Coronary Artery Bypass Graft surgery: a prospective, randomized, controlled clinical trial. J Cardiothorac Vasc Anesth 25(6): 908-916, 2011.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Sharifi M,
    2. Fares W,
    3. Abdel-Karim I,
    4. Koch JM,
    5. Sopko J,
    6. Adler D
    : Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris. Am J Cardiol 93(12): 1533-1535, 2004.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Pini M,
    2. Rhodes DH,
    3. Castellanos KJ,
    4. Hall AR,
    5. Cabay RJ,
    6. Chennuri R,
    7. Grady EF,
    8. Fantuzzi G
    : Role of IL-6 in the resolution of pancreatitis in obese mice. J Leukoc Biol 91(6): 957-966, 2012.
    OpenUrlCrossRefPubMed
  42. ↵
    1. Boreddy SR,
    2. Sahu RP,
    3. Srivastava SK
    : Benzyl isothiocyanate suppresses pancreatic tumor angiogenesis and invasion by inhibiting HIF-α/VEGF/Rho-GTPases: pivotal role of STAT-3. PLoS One 6(10): e25799. Epub 2011.
    OpenUrlCrossRefPubMed
  43. ↵
    1. Grote VA,
    2. Kaaks R,
    3. Nieters A,
    4. Tjønneland A,
    5. Halkjær J,
    6. Overvad K,
    7. Skjelbo Nielsen MR,
    8. Boutron-Ruault MC,
    9. Clavel-Chapelon F,
    10. Racine A,
    11. Teucher B,
    12. Becker S,
    13. Pischon T,
    14. Boeing H,
    15. Trichopoulou A,
    16. Cassapa C,
    17. Stratigakou V,
    18. Palli D,
    19. Krogh V,
    20. Tumino R,
    21. Vineis P,
    22. Panico S,
    23. Rodríguez L,
    24. Duell EJ,
    25. Sánchez MJ,
    26. Dorronsoro M,
    27. Navarro C,
    28. Gurrea AB,
    29. Siersema PD,
    30. Peeters PH,
    31. Ye W,
    32. Sund M,
    33. Lindkvist B,
    34. Johansen D,
    35. Khaw KT,
    36. Wareham N,
    37. Allen NE,
    38. Travis RC,
    39. Fedirko V,
    40. Jenab M,
    41. Michaud DS,
    42. Chuang SC,
    43. Romaguera D,
    44. Bueno-de-Mesquita HB,
    45. Rohrmann S
    : Inflammation marker and risk of pancreatic cancer: a nested case-control study within the EPIC cohort. Br J Cancer 106(11): 1866-1874, 2012.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Ribatti D,
    2. Crivellato E
    : Mast cells, angiogenesis and cancer. Adv Exp Med Biol 716: 270-288, 2011.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Norrby K
    : Mast cells and angiogenesis. APMIS 110(5): 355-371, 2002.
    OpenUrlCrossRefPubMed
  46. ↵
    1. Alexakis N,
    2. Halloran C,
    3. Raraty M,
    4. Ghaneh P,
    5. Sutton R,
    6. Neoptolemos JP
    : Current standards of surgery for pancreatic cancer. Br J Surg 91: 1410-1427, 2004.
    OpenUrlCrossRefPubMed
    1. Sakorafas GH,
    2. Friess H,
    3. Balsiger BM,
    4. Büchler MW,
    5. Sarr MG
    : Problems of reconstruction during pancreatoduodenectomy. Dig Surg 18: 363-369, 2001.
    OpenUrlPubMed
    1. Büchler M,
    2. Friess H,
    3. Klempa I,
    4. Hermanek P,
    5. Sulkowski U,
    6. Becker H,
    7. Schafmayer A,
    8. Baca I,
    9. Lorenz D,
    10. Meister R,
    11. et al
    : Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg 163(1): 125-130, 1992.
    OpenUrlCrossRefPubMed
    1. Pederzoli P,
    2. Bassi C,
    3. Falconi M,
    4. Camboni MG
    : Efficacy of octreotide in the prevention of complications of elective pancreatic surgery: Italian Study Group. Br J Surg 81: 265-269, 1994.
    OpenUrlPubMed
    1. Friess H,
    2. Beger HG,
    3. Sulkowski U,
    4. Becker H,
    5. Hofbauer B,
    6. Dennler HJ,
    7. Büchler MW
    : Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg 82: 1270-1273, 1995.
    OpenUrlPubMed
    1. Yeo CJ,
    2. Cameron JL,
    3. Maher MM,
    4. Sauter PK,
    5. Zahurak ML,
    6. Talamini MA,
    7. Lillemoe KD,
    8. Pitt HA
    : A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 222: 580-588, 1995.
    OpenUrlCrossRefPubMed
    1. Bassi C,
    2. Falconi M,
    3. Molinari E,
    4. Mantovani W,
    5. Butturini G,
    6. Gumbs AA,
    7. Salvia R,
    8. Pederzoli P
    : Duct-to-mucosa versus end-to-sidepancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial. Surgery 134: 766-771, 2003.
    OpenUrlCrossRefPubMed
  47. ↵
    1. Bassi C,
    2. Falconi M,
    3. Salvia R,
    4. Mascetta G,
    5. Molinari E,
    6. Pederzoli P
    : Management of complications after pancreaticoduodenectomy in a high volume centre: results on 150 consecutive patients. Dig Surg 18: 453-457, 2001.
    OpenUrlCrossRefPubMed
  48. ↵
    1. Bartoli FG,
    2. Arnone GB,
    3. Ravera G,
    4. Bachi V
    : Pancreatic fistula and relative mortality in malignant disease after pancreatico-duodenectomy: review and statistical meta-analysis regarding 15 years of literature. Anticancer Res 11: 1831-1148, 1991.
    OpenUrlPubMed
  49. ↵
    1. Friess H,
    2. Malfertheiner P,
    3. Isenmann R,
    4. Kühne H,
    5. Beger HG,
    6. Büchler MW
    : The risk of pancreaticointestinal anastomosis can be predicted preoperatively. Pancreas 13: 202-208, 1996.
    OpenUrlPubMed
  50. ↵
    1. Bosco G,
    2. Guizzon L,
    3. Yang Z,
    4. Camporesi E,
    5. Casarotto A,
    6. Bosio C,
    7. Mangar D,
    8. Chen C,
    9. Cannato M,
    10. Toniolo L,
    11. Garetto G,
    12. Nasole E,
    13. Bassi C
    : Effect of hyperbaric oxygenation and gemcitabine on apoptosis of pancreatic ductal tumor cells in vitro. Anticancer Res 33(11): 4827-32, 2013.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 34, Issue 6
June 2014
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preconditioning with Hyperbaric Oxygen in Pancreaticoduodenectomy: a Randomized Double-blind Pilot Study
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Preconditioning with Hyperbaric Oxygen in Pancreaticoduodenectomy: a Randomized Double-blind Pilot Study
GERARDO BOSCO, ANDREA CASAROTTO, EMANUELE NASOLE, ENRICO CAMPORESI, ROBERTO SALVIA, FRANCESCO GIOVINAZZO, SARA ZANINI, GIUSEPPE MALLEO, ANDREA DI TANO, ALESSANDRO RUBINI, VINCENZO ZANON, DEVANAND MANGAR, CLAUDIO BASSI
Anticancer Research Jun 2014, 34 (6) 2899-2906;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Preconditioning with Hyperbaric Oxygen in Pancreaticoduodenectomy: a Randomized Double-blind Pilot Study
GERARDO BOSCO, ANDREA CASAROTTO, EMANUELE NASOLE, ENRICO CAMPORESI, ROBERTO SALVIA, FRANCESCO GIOVINAZZO, SARA ZANINI, GIUSEPPE MALLEO, ANDREA DI TANO, ALESSANDRO RUBINI, VINCENZO ZANON, DEVANAND MANGAR, CLAUDIO BASSI
Anticancer Research Jun 2014, 34 (6) 2899-2906;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Low-dose Andrographolide Synergizes With Cytarabine or Vincristine in Plasma Cell Neoplasm Cell Lines
  • Enzalutamide Enhanced Honokiol-induced Apoptotic Insults to Drug-resistant Glioblastoma Cells via an Intrinsic Bak-mitochondrion-caspase Cascade Mechanism
  • Milk Extracellular Vesicle–mediated Delivery of siPRNP Suppresses Growth and Wound Closure in PC-3M Prostate Cancer Cells
Show more Experimental Studies

Keywords

  • pancreaticoduodenectomy
  • HBO
  • hyperbaric
  • pre-conditioning
  • surgery
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire